QuidelOrtho Corp QDEL
Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes. Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S., U.K. and China and with sales centers, administrative offices and warehouses located throughout the world.
We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as for individual, non-professional, OTC use.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.73B | $2.78B | $3.00B | $3.27B | $1.70B | $1.66B | — |
| R&D | $186.2M | $218.7M | $245.0M | $187.9M | $95.7M | $84.3M | — |
| SG&A | $746.3M | $766.8M | $763.2M | $621.0M | $239.6M | $180.7M | — |
| Operating income | -$919.2M | -$1.96B | $139.1M | $843.7M | $906.0M | $1.06B | — |
| Interest expense | $177.6M | $163.5M | $147.6M | $75.7M | $5.8M | $8.5M | — |
| Pre-tax income | -$1.11B | -$2.13B | -$29.1M | $735.9M | $900.3M | $1.04B | — |
| Income tax | $24.1M | $79.5M | $19.0M | $187.2M | $196.1M | $230.0M | — |
| Net income | -$1.13B | -$2.05B | -$10.1M | $548.7M | $704.2M | $810.3M | — |
| EPS, basic | -16.69 | -30.54 | -0.15 | 9.66 | 16.74 | 19.24 | — |
| EPS, diluted | -16.69 | -30.54 | -0.15 | 9.56 | 16.43 | 18.60 | — |
| Shares, diluted (wtd. avg.) | $67.8M | $67.2M | $66.8M | $57.4M | $42.9M | $43.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $169.8M | $98.3M | $119.5M | $293.9M | $802.8M | $489.9M | $52.8M |
| Short-term investments | — | $0 | $48.4M | $52.1M | $25.7M | — | — |
| Receivables | $417.0M | $282.4M | $303.3M | $453.9M | $378.0M | — | — |
| Inventory | $577.6M | $533.7M | $577.8M | $524.1M | $198.8M | — | — |
| Total current assets | $1.45B | $1.22B | $1.31B | $1.58B | $1.44B | — | — |
| Property, plant and equipment | — | — | $1.44B | $1.34B | $349.2M | — | — |
| Goodwill | $0 | $649.5M | $2.49B | $2.48B | $337.0M | — | — |
| Other intangibles | $2.56B | $2.74B | $2.93B | $3.12B | $98.7M | — | — |
| Total assets | $5.77B | $6.42B | $8.56B | $8.86B | $2.43B | — | — |
| Accounts payable | $279.4M | $246.0M | $294.8M | $283.3M | $101.5M | — | — |
| Short-term debt | $178.3M | $341.8M | $139.8M | $207.5M | $300.0K | — | — |
| Total current liabilities | $966.1M | $998.8M | $833.8M | $1.01B | $323.5M | — | — |
| Long-term debt | $2.70B | $2.49B | $2.42B | $2.65B | — | — | — |
| Total liabilities | $3.85B | $3.44B | $3.56B | $3.92B | $501.0M | — | — |
| Retained earnings | -$996.0M | $135.8M | $2.19B | $2.20B | $1.65B | — | — |
| Total equity | $1.92B | $2.98B | $5.01B | $4.93B | $1.93B | $1.33B | $559.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $105.2M | $83.0M | $280.2M | $885.3M | $805.9M | $629.7M | — |
| Depreciation and amortisation | $442.0M | $453.4M | $457.2M | $283.6M | $52.7M | $48.8M | — |
| Stock-based compensation | $45.9M | $42.1M | $51.6M | $48.4M | $25.4M | $21.0M | — |
| Capital expenditure | $188.2M | $195.1M | $209.3M | $140.9M | $292.8M | $64.9M | — |
| Investing cash flow | -$192.7M | -$149.9M | -$187.6M | -$1.64B | -$319.5M | -$63.3M | — |
| Financing cash flow | $155.8M | $48.8M | -$265.8M | $252.0M | -$173.1M | -$130.3M | — |
| Buybacks | $0 | $0 | $7.2M | $74.3M | $103.5M | $43.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001906324-26-000018.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $42.18B | 40.9x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.59B | 29.6x | 0.5% |
| CLDX | Celldex Therapeutics, Inc. | $3.12B | — | -78.0% |
| NEOG | NEOGEN CORP | $2.58B | — | -2.7% |
| NTLA | Intellia Therapeutics, Inc. | $1.79B | — | 16.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $873.6M | — | — |
| TKNO | Alpha Teknova, Inc. | $371.5M | — | 7.4% |
| MYGN | MYRIAD GENETICS INC | $305.1M | — | -1.6% |